Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?

Blood cancer discovery·2026
Same author

PET-guided early identification of CAR-T candidates in diffuse large b-cell lymphoma: a multidisciplinary expert consensus.

European journal of nuclear medicine and molecular imaging·2026
Same author

Retraction Note: MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia.

Leukemia·2026
Same author

Coordinated immune-epithelial dynamics in the nasal epithelium protect against respiratory virus infection.

bioRxiv : the preprint server for biology·2026
Same author

Reactive and therapy induced bone marrow changes linked to systemic infectious and non-infectious disorders including MAS/HLH report from the European association for haematopathology, Dubrovnik 2024.

Virchows Archiv : an international journal of pathology·2026

Related Experiment Video

Updated: Oct 4, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.9K

Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning

Maher Albitar1, Hong Zhang2, Andre Goy3

  • 1Genomic Testing Cooperative, LCA, Irvine, CA, 92618, USA. malbitar@genomictestingcooperative.com.

Blood Cancer Journal
|February 2, 2022
PubMed
Summary

Researchers developed a machine learning model to classify diffuse large B-cell lymphoma (DLBCL) into four survival subgroups using gene expression. This approach identifies patients who may not benefit from standard R-CHOP therapy, guiding alternative treatment decisions.

More Related Videos

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.9K
Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

971

Related Experiment Videos

Last Updated: Oct 4, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.9K
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.9K
Constructing and Visualizing Models using Mime-based Machine-learning Framework
06:19

Constructing and Visualizing Models using Mime-based Machine-learning Framework

Published on: July 22, 2025

971

Area of Science:

  • Oncology
  • Bioinformatics
  • Genomics

Background:

  • Diffuse large B-cell lymphoma (DLBCL) exhibits biological heterogeneity, complicating clinical stratification.
  • Existing biological subgroups in DLBCL show significant clinical overlap, limiting treatment precision.

Purpose of the Study:

  • To develop and validate a machine learning model for stratifying DLBCL patients into distinct survival subgroups.
  • To utilize targeted transcriptome data for predicting patient survival outcomes in DLBCL.

Main Methods:

  • Employed machine learning algorithms to analyze gene expression data from 180 genes.
  • Validated the predictive model using independent patient cohorts to ensure reliability.

Main Results:

  • Successfully stratified DLBCL patients into four distinct survival subgroups.
  • The model demonstrated reliable prediction of survival outcomes based on gene expression profiles.
  • Multivariate analysis confirmed that TP53 mutations are the sole independent prognostic biomarker.

Conclusions:

  • This novel gene expression-based stratification offers a more precise approach to DLBCL patient management.
  • The model can identify DLBCL patients unlikely to respond to R-CHOP therapy, suggesting alternative treatments or clinical trials.
  • This strategy aids in personalizing DLBCL treatment by predicting response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy.